Latest Leukemia News
Imatinib Effective Over Long Term in Refractory Leukemia
Imatinib mesylate (Gleevec®) therapy shows lasting safety and efficacy in chronic-phase chronic myeloid leukemia patients in whom interferon-alpha treatment has failed.
Taken from LeukemiaLinks, your monthly source of leukemia news, research updates, clinical trials and events sponsored by The Leukemia & Lymphoma Society (LLS). For even more information, regularly visit their Patient Services and Disease Information Web sections.
| Print article | This entry was posted by FOH Team Leaders on February 22, 2008 at 8:32 am, and is filed under Cancer Research Notes. Follow any responses to this post through RSS 2.0. Both comments and pings are currently closed. |
Comments are closed.
